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Abstract
Colistin has been re-introduced into clinical practice for the treatment of carbapenem-resistant Gram-negative bacteria. Studies in the
last decade attempted to reconstruct the path that present-day medications undergo prior to clinical use. In this review, we summarize
the results of recent clinical studies. Colistin was associated with lower mortality than no effective treatment and higher unadjusted
mortality than b-lactams in non-randomized clinical studies. However, it was administered to sicker patients with carabapenem-resistant
bacteria. Overall, nephrotoxicity rates were not higher with colistin in these studies, and colistin-induced nephrotoxicity is reversible in
most patients. The emergence of colistin resistance has been described in high-use settings. Synergy with carbapenem, rifampin and
other antibiotics has been reported in vitro. Randomized controlled trials are ongoing or in planning to assess this and other aspects of
colistin use in clinical practice.
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Introduction
The polymyxin group of polypeptide antibiotics, discovered in
the 1940s, were among the ﬁrst antibiotics with signiﬁcant
activity against Gram-negative bacteria [1,2]. Polymyxin E (colis-
tin) and polymyxin B are the main antibiotics of this group and
the only polymyxins used clinically. Following reports on neph-
rotoxicity and neurotoxicity in the 1970s, they were largely
replaced by other antibiotics [3,4]. In the last two decades, the
paucity of novel antibiotics with which to treat drug-resistant
infections, especially those caused by Gram-negative pathogens,
has led to their reconsideration as a therapeutic option [5]. The
current review focuses on colistin, rather than polymyxin B,
because of its wider use in current clinical practice.
Mechanism of Action
Most investigations have been conducted with polymyxin B,
which is regarded as a model polymyxin. Colistin has a similar
structure to polymyxin B, and is believed to have an identical
mechanism of action [6]. The initial target of the antimicrobial
activity of polymyxins is the lipopolysaccharide (LPS) compo-
nent of the outer membrane [7,8]. The polymyxins have a
strong positive charge and a hydrophobic acyl chain that give
them a high binding afﬁnity for LPS molecules. They interact
electrostatically with these molecules and competitively displace
divalent cations from them, causing disruption of the membrane
[9]. The result of this process is an increase in the permeability
of the cell envelope, leakage of cell contents, and, subsequently,
cell death [10,11]. Some authors argue that interaction with
membranes is indeed a part of the action of polymyxins, but is
not actually the lethal event [9]. The exact mechanism by which
the polymyxins induce bacterial killing is still unknown, and mul-
tiple bacterial cell targets may be involved [12–14]. Polymyxins
also bind to the lipid A portion of LPS and, in animal studies,
block many of the biological effects of endotoxin [15].
Spectrum of Activity and Resistance
Colistin’s in vitro activity includes most aerobic Gram-negative
rods, except for Neisseria, Proteus, Serratia, Providencia, Brucella
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and Edwardsiella species, Pseudomonas mallei, and Burkholderia
cepacia [1,16]. It causes rapid bacterial killing in a concentra-
tion-dependent manner [2]. It has in vitro activity against some
multidrug-resistant (MDR) Gram-negative pathogens, including
Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella
pneumoniae, [17] and Stenotrophomonas maltophilia. P. aerugin-
osa susceptibility and A. baumannii susceptibility are deﬁned as
MICs of £4 and £2 mg/L colistin sulphate, respectively, accord-
ing to the European Committee on Antimicrobial Susceptibility
Testing [18], and as an MIC of £2 mg/L for both bacteria
according to the CLSI [19]. Colistin has no activity against
Gram-positive bacteria, all cocci, and anaerobes [1,20]. It has
also been reported to be potentially active against several
mycobacterial species, including Mycobacterium tuberculosis [1].
Rates of colistin resistance have been relatively low, proba-
bly because of its infrequent use. Nevertheless, resistance has
recently been identiﬁed in several Gram-negative bacterial spe-
cies. Ko et al. [21] identiﬁed a high rate of colistin/polymyxin
resistance in A. baumannii strains belonging to subgroups II and
III in Korea, on the basis of rpoB gene analysis. Heteroresis-
tance to colistin (i.e. the presence of colistin-resistant subpop-
ulations within a microbial population that is susceptible
according to its MIC) in MDR A. baumannii has been reported
in 23–100% of clinical isolates in few studies, but the clinical
relevance of this heteroresistance was not investigated [22–
24]. Heteroresistance to colistin has also been recently
detected in other species, including K. pneumoniae [25,26] and
P. aeruginosa [27]. The emergence of colistin-resistant K. pneu-
moniae has been described following widespread use of colistin
[28]. Resistance of P. aeruginosa to colistin is a growing prob-
lem [29,30], and has been described most commonly in
patients with cystic ﬁbrosis (CF) who have received aerosol-
ized colistin therapy [31,32]. The most common mechanism of
colistin resistance is modiﬁcation of LPS [33]. Several other
mechanisms have been suggested, most of which involve
changes in the outer membrane [20,33]. An efﬂux pump/potas-
sium system may also be associated with resistance to poly-
myxin B [34]. Paenibacillus polymyxa subspecies colistinus, the
organism that produces colistin, also produces colistinase,
which inactivates colistin. However, enzymatic resistance of
bacteria to colistin has not been reported in clinical practice
[1]. Recently, colistin resistance mediated by complete loss of
LPS production has been described in A. baumannii strains [35].
Formulations, Dosage, and Route of
Administration
There are two forms of colistin available: colistin sulphate
and the commercially available parenteral formulation colisti-
methate sodium (colistin sulphomethate sodium, colistin
methanesulphonate). Colistimethate sodium is a prodrug
[36]. In aqueous solution, colistimethate sodium undergoes
spontaneous hydrolysis to the active form colistin [20]. Co-
listimethate sodium is administered parenterally, intrave-
nously, or intramuscularly, as it is less toxic than colistin
sulphate [37]. The intramuscular injection, which is rarely
used in clinical practice, may cause severe local pain, and
absorption is variable. Colistin sulphate is administered either
orally (for bowel decontamination, without absorption) or
topically (for the treatment of bacterial skin infections) [1].
Both colistimethate sodium and colistin can be given via inha-
lation, but colistin may result in a higher frequency of bron-
choconstriction than colistimethate sodium (see below).
Colistimethate sodium can also be administered by the intra-
thechal or intraventricular routes [1]. Colistimethate sodium
is hydrolysed in aqueous solutions to colistin in a concentra-
tion-dependent manner, so it should be administered shortly
after reconstitution to avoid the toxicity associated with
colistin [38].
There are two common commercially available parenteral
formulations of colistimethate sodium [20]. Colomycin injec-
tion, which is manufactured and used in Europe, is provided
in vials containing 500 000, 106 or 2 ·106 international units
(IU) of colistimethate sodium. An IU of colistin is deﬁned as
the minimal concentration that inhibits the growth of Escheri-
chia coli 95 I.S.M in 1 mL of broth at pH 7.2 [39], and 106 IU
is considered to be equivalent to 80 mg of colistimethate
sodium [40]. Coly-Mycin M Parenteral, which is manufac-
tured and used in the USA, contains 150 mg of ‘colistin base
activity’ per vial, equivalent to 360 mg of colistimethate
sodium per vial and to 4.5 ·106 IU of colistimethate sodium
[20]. The need for uniform dosing of colistimethate sodium
is obvious, and this would avoid confusion. As there is no
direct relationship between IUs determined in vitro and the
pharmacodynamics of colistimethate sodium in vivo, it has
been suggested that the use of milligrams of colistimethate
sodium is preferable [41]. The doses of colistimethate
sodium used for systemic infections in adults range widely,
between 240 and 720 mg daily (i.e. 3–9 ·106 IU/day), in two
to four divided doses. The pharmacokinetics of intravenous
colistin are discussed extensively by Couet et al. [42] in this
issue.
Penetration of colistin through the blood–brain barrier to
the central nervous system (CNS) is poor, and is estimated
to be approximately 5% [43]. In different studies, enhance-
ment of penetration during meningitis and inﬂammation has
been reported to range between none [44] and 25–67%
[45,46]. In a review of case reports, the doses of colistimet-
hate sodium used in intrathecal or intraventricular adminis-
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tration for meningitis ranged between 3.2 and 40 mg
(40 000–500 000 IU) per day [47]. The paucity of data pre-
vents an analysis of the association between dosing and
treatment success. In a pharmacokinetic (PK) study, a daily
dose of 4.8 mg (60 000 IU) of intraventricular colistimethate
sodium resulted in a trough colistin cerebrospinal ﬂuid level
of 2.2 mg/L, whereas regimens of 2.4 mg (30 000 IU) every
12 h or 4.8 mg (60 000 IU) every 12 h led to a trough con-
centration of >5 mg/L (the target MIC is >2 mg/L) (Cusato
et al., 21st ECCMID, 2011, Abstract P814).
Distribution to the biliary tract, pleural ﬂuid and joint ﬂuid
is considered to be similarly poor [48]. A prospective study
conducted in 13 critically ill adult patients found that the
intravenous administration of 480 mg (6 ·106 IU) of colisti-
methate sodium per day resulted in suboptimal plasma con-
centrations of colistin, which were undetectable in
bronchoalveoalar lavage ﬂuid [49]. Another study in two crit-
ically ill patients demonstrated good penetration into lung
tissue and called for further studies [50]. Differences in
results were explained by dilutional effects and colistimethate
sodium intravenous dosage. Trials assessing the pharmacoki-
netics of colistin (plasma levels and concentrations in pulmo-
nary epithelial lining ﬂuid) are ongoing [51,52].
Toxicity
Nephrotoxicity is one of the commonly observed adverse
effects following intravenous administration of colistimethate
sodium. In studies comparing treatment with colistimethate
sodium with or without other antibiotics vs. other antibiotic
regimens, nephrotoxicity was signiﬁcantly higher with colisti-
methate sodium (or polymyxin B) in six studies, similar to
that with comparators in ﬁve (two of which claimed no
events), and lower in two (Table 1). Rates of nephrotoxicity
in recent studies designed to assess this outcome have ran-
ged from 6% to 14% in some [53–57] and from 32% to 55%
in others [58–63]. The wide range of nephrotoxicity rates
can be at least partly explained by different deﬁnitions of
renal failure (see Table S1). Some studies used any of the
RIFLE criteria (risk, injury, failure, loss, and end-stage kidney
disease) [64], some used the threshold of failure or above,
and others deﬁned renal failure as creatinine >2 mg/dL. Risk
factors for nephrotoxicity found in different studies included
older age [59,62], pre-existing renal insufﬁciency [65], hypo-
albuminaemia [60], and concomitant use of non-steroidal
anti-inﬂammatory drugs [60] or vancomycin [62]. Higher
dosing is associated with renal failure, with some studies
identifying the total cumulative dose as predictive of renal
failure [4,57,58], and others the daily dose [59,62,63]. The
time to nephrotoxicity was not reported in most studies.
Four studies reported that most cases occurred within the
ﬁrst week of treatment [59,61–63]. Studies monitoring
patients for up to 1–3 months after treatment demonstrated
reversibility of renal failure in at least 88% of patients
[54,58,60]. Overall, rates of nephrotoxicity are probably
lower today than those observed in old studies [4]. Explana-
tions for the lower toxicity include fewer chemical impurities
in colistimethate sodium, better intensive-care unit (ICU)
monitoring, and avoidance of co-administration of other
nephrotoxic drugs [66,67]. Recent observations have sug-
gested that, at least in CF patients, colistimethate sodium
may actually be less nephrotoxic than aminoglycosides [68].
Neurotoxicity is less common than nephrotoxicity. Clini-
cal manifestations include dizziness, muscle weakness, pares-
thesias, partial deafness, visual disturbances, vertigo,
confusion, hallucinations, seizures, ataxia, and neuromuscular
blockade. Paresthesias constitute the most common clinical
manifestation, being reported in approximately 27% of cases
with the use of intravenous colistimethate sodium. Neuro-
toxic effects are usually mild, and resolve after prompt dis-
continuation of the antibiotic [67].
Apnoea and respiratory failure, which are feared complica-
tions of neuromuscular blockade, have not been reported
with intravenous colistimethate sodium in the recent litera-
ture [67], but a case has been described when intravenous
administration was combined with inhaled colistimethate
sodium [69]. Other adverse events of inhaled colistimethate
sodium may include bronchospasm and hypersensitivity pneu-
monitis [70], but recent studies in critically ill patients with-
out CF have not demonstrated these adverse events [71–
79].
Clinical Experience with Intravenous
Colistimethate Sodium
Treatment with colistimethate sodium has been described
worldwide in the last decade. Table 1 summarizes compara-
tive and non-comparative clinical studies assessing colistimet-
hate sodium and polymyxin B. Most studies reported on
MDR A. baumannii and P. aeruginosa infections. A few recent
studies have also reported on carbapenem-resistant K. pneu-
moniae infections. Non-comparative studies described series
of patients treated with colistimethate sodium (Table 1), and
concluded that outcomes were acceptable, considering the
severity of infection and underlying patient illnesses. All but
one were retrospective, and colistimethate sodium was usu-
ally administered in combination with other antibiotics. The
most common source of infection was pneumonia (usually
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ventilator-associated pneumonia (VAP)), and all-cause mortal-
ity ranged between 20% and 52%. In the largest cohort,
which included 258 patients, 60% of patients had pneumonia,
and the in-hospital mortality rate was 34.9% [80]. In a single
prospective older study, colistimethate sodium was adminis-
tered as monotherapy, and the mortality rate was 37% [65].
Twelve comparative prospective or retrospective clinical
studies were identiﬁed (Table 1). Most compared treatment
with colistimethate sodium against Gram-negative bacteria
resistant to all other antibiotics with b-lactams (usually car-
bapenems) given according to the antibiotic susceptibilities of
the infecting bacteria. Two compared colistimethate sodium
with inappropriate antibiotics given to bacteria susceptible
only to colistin. As previously, the most common source of
infection was pneumonia (median of 62% patients), and most
patients treated with colistimethate sodium were concomi-
tantly treated with other antibiotics, although the infecting
bacteria were frequently susceptible only to colistin. The
comparative all-cause mortality results are summarized in
Fig. 1. One small quasi-randomized trial, two retrospective
studies using some type of matching procedure and four pro-
spective non-matched comparative studies showed no differ-
ence or a higher mortality rate with colistimethate sodium,
with a pooled OR for death of 1.40 (95% CI 1.07–1.84),
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FIG. 1. All-cause mortality in studies comparing colistimethate sodium with other antibiotics. d.f., degrees of freedom.
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indicating a signiﬁcantly higher mortality rate with colistimet-
hate sodium. The largest study, contributing the highest
weight in this comparison, was a prospective cohort study
comparing colistimethate sodium (mostly monotherapy) with
carbapenems or ampicillin–sulbactam that showed a signiﬁ-
cantly higher mortality rate with colistin [81]. The multivari-
able adjusted ORs for 30-day mortality in this study were
1.44 (95% CI 0.91–2.26) overall (N = 495) and 1.99
(95% CI 1.06–3.77) for bacteraemic patients (N = 220).
Unlike in other studies, a large percentage of patients treated
with colistimethate sodium had infections caused by carbape-
nem-resistant K. pneumoniae, and the difference in mortality
was attributable to this subgroup of patients. Four non-
matched retrospective studies showed a uniformly higher
mortality rate with colistimethate sodium (pooled OR 2.65,
95% CI 1.76–3.99). The two studies comparing colistimet-
hate sodium with inappropriate antibiotic treatment both
showed a lower mortality rate with colistimethate sodium
(pooled OR 0.51, 95% CI 0.24–1.08).
In summary, contemporary clinical studies have demon-
strated that treatment with colistimethate sodium is proba-
bly better than no treatment at all, on the basis of multiple
cohort studies showing acceptable outcomes with colistimet-
hate sodium, and two comparative studies showing nearly
halved mortality with colistimethate sodium as compared
with ineffective treatment. The comparison with other cov-
ering antibiotics is hindered by the inherent differences
between patients infected with bacteria susceptible only to
colistin and those infected with less resistant bacteria. The
clear trend in ORs from the least to the most biased study
design (Fig. 1, top to bottom) attests to the effect of patient
differences on results. The comparison is further complicated
by the fact that colistimethate sodium was usually given in
combination with other antibiotics, and infections are fre-
quently polymicrobial. A compilation of unadjusted mortality
results from all studies shows signiﬁcantly a higher mortality
rate with colistimethate sodium. We believe that there is a
survival advantage to b-lactams that is probably smaller than
that shown in the unadjusted analysis.
Antibiotic Combinations Including
Colistimethate Sodium
Some in vitro studies have indicated synergy between colistin
and carbapenems for colistin-susceptible/carbapenem-resis-
tant Gram-negative bacteria. Synergy deﬁnition in these trials
was based on standard methodology: a 2 log10 decrease in
CFU/mL between the combination and the most active single
agent at the different time-points [82]. Synergy was observed
with imipenem against A. baumannii, [83–85], P. aeruginosa
[27], and low-inoculum Enterobacter cloacae [86], and with
doripenem against A. baumannii, P. aeruginosa, E. coli, and
K. pneumoniae [87–89]. Imipenem–colistin synergy was
reported in 50% of K. pneumoniae strains with the blaVIM-1
genotype [82]. An in vitro PK/pharmacodynamic study also
demonstrated substantial reductions in regrowth of P. aeru-
ginosa with a colistin–doripenem combination and reduction
and delay in the emergence of colistin-resistant subpopula-
tions [89]. In vitro synergy with ceftazidime and rifampin
against P. aeruginosa and A. baumannii has been suggested
[90–93]. Other in vitro studies demonstrated signiﬁcant syn-
ergy when colistin was combined with a glycopeptide against
A. baumannii [94,95]. A small in vitro study suggested synergy
with minocycline against the same organism [96]. Possible
mechanisms for synergy with colistin and carbapenems or
rifampin are subpopulation synergy and mechanistic synergy
[27] (Bulitta, PAGE (population approach group in Europe)
2010, Abstract 1918). In subpopulation synergy, one drug
kills the subpopulations that are resistant to the other drug
and vice versa. Mechanistic synergy means that, because each
drug acts on a different cellular pathway, one drug increases
the rate or extent of killing caused by the other drug [27].
Concerns regarding colistin monotherapy that have been
previously raised include heteroresistance among Gram-nega-
tive bacterial populations exposed to colistin alone [23]. The
clinical signiﬁcance of this heteroresistance remains unknown
[97]. Regrowth with colistin monotherapy was demonstrated
in several in vitro studies [91,98], even at supraclinical doses
[26,99]. The ampliﬁcation of colistin-resistant subpopulations
in heteroresistant strains has been shown to contribute to
the regrowth following colistin monotherapy [26,98,100].
Recent PK studies have indicated that the colistin Cmax val-
ues typically achieved following administration of colistimet-
hate sodium at the recommended doses are low [42]. Given
these data, there is a strong theoretical basis for the use of
colistin as part of combination antimicrobial therapy to maxi-
mize antimicrobial activity.
Clinical studies have yet to show whether colistimethate
sodium combination therapy offers a clinical advantage. Fala-
gas et al. retrospectively assessed 258 patients treated with
colistimethate sodium monotherapy or combination therapy
[80,101,102]. Only 52.3% (136) of patients had pathogens
susceptible only to colistin. Most patients (86%) were hospi-
talized in the ICU, and 92.3% of infections were caused by
A. baumannii or P. aeruginosa. The most common infection
was pneumonia (60%), and bacteraemia was present in 13%
of patients. In total, infection was cured in 83.3% of patients
who received colistimethate sodium monotherapy (36
patients) or colistimethate sodium combined with merope-
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nem (162 patients). In the adjusted analyses, combination
therapy did not offer a survival advantage overall or among
patients with infections susceptible only to colistin . Other,
smaller, observational studies found no signiﬁcant differences
between colistin monotherapy and combination therapies. A
retrospective study evaluated eight patients with diabetic
foot caused by MDR P. aeruginosa, and found no difference in
clinical response and safety between colistin alone and colis-
tin–rifampin or colistin–imipenem combinations [103]. Linden
et al. [104] found no difference in clinical response to either
colistin alone or colistin combined with amikacin or an anti-
pseudomonal b-lactam in a prospective study evaluating 23
ICU patients with serious MDR P. aeruginosa infections.
In a randomized controlled trial (RCT), 53 CF patients
colonized with colistin-sensitive P. aeruginosa were allocated
to either intravenous colistimethate sodium alone or colisti-
methate sodium combined with an antipseudomonal drug
during a respiratory exacerbation. All patients showed clini-
cal improvement, and mean forced vital capacity increased
signiﬁcantly in the dual-therapy group [105]. Colistin com-
bined with rifampin was reported to be effective in the treat-
ment of A. baumannii pneumonia with/without bacteraemia in
ICU patients in two prospective uncontrolled small studies
[106,107].
The limitations of the available data on the clinical efﬁcacy
of colistin combinations include low numbers of patients,
study design, heterogeneity in the deﬁnition of outcomes,
variability in the dosing regimens, differences in the suscepti-
bility testing methods, lack of PK information for colistimet-
hate sodium and formed colistin, and the fact that most
studies do not stratify outcome by severity of illness [97].
Several trials assessing colistimethate sodium combination
treatment are currently being planned or ongoing. Two
RCTs comparing colistimethate sodium with colistimethate
sodium plus imipenem for invasive infections caused by carb-
apenem-resistant Gram-negative bacteria are currently being
planned in the USA, Europe, Israel, and Greece, funded by
the National Institutes of Health and the EU 7th framework
(Keith Kaye and Johan Mouton, personal communication).
Two other trials are ongoing in Thailand, comparing colisti-
methate sodium alone with colistimethate sodium plus fosfo-
mycin [108] or colistimethate sodium plus rifampicin [109]
for infections caused by MDR A. baumannii.
In summary, although in vitro data are promising, there is
no clinical proof of an advantage for colistimethate sodium
combination therapy. In existing studies, colistin was usually
given in combination with other antibiotics. In vitro data do
not necessarily translate into clinical beneﬁt [110]. Well-
designed randomized trials targeting relevant patient popula-
tions are underway.
Aerosolized Colistimethate Sodium in
Patients without CF
One small retrospective report and one case control–study
claimed success for aerosolized colistimethate sodium, with-
out intravenous antibiotics, for the treatment of pneumonia
[71,72]. Several small retrospective studies assessed aerosol-
ized colistimethate sodium with concomitant intravenous
therapy for the treatment of MDR Gram-negative pneumo-
nia. These studies demonstrated clinical success rates
between 57% [75,76] and 87.5% [78] with aerosolized colisti-
methate sodium (in addition to intravenous colistin). One
prospective study demonstrated bacteriological and clinical
response of 83.3% with adjunctive aerosolized colistimethate
sodium [77]. Two retrospective comparative studies evalu-
ated aerosolized plus intravenous colistimethate sodium with
intravenous colistimethate sodium alone for the treatment of
VAP. These studies demonstrated signiﬁcantly higher clinical
cure rates with dual therapy (54.5% vs. 32% [73] and 79.5%
vs. 60.5% [74]), without a signiﬁcant difference in overall
mortality. In an open-label RCT comparing colistimethate
sodium inhalation with placebo in 100 evaluable patients with
Gram-negative VAP in Thailand, there was a signiﬁcant
advantage for colistimethate sodium inhalation in microbio-
logical outcome but no improvement in clinical outcomes
[79]. Most patients in this trial were treated intravenously
with colistimethate sodium or a carbapenem. At the end of
follow-up (day 28), 60.9% of patients in the intervention
group had a favourable microbiological outcome, and 51%
had a favourable clinical outcome, as compared with 38.2%
and 53.1%, respectively, in the control group. There was no
signiﬁcant difference between the study arms in overall mor-
tality, mortality caused by VAP, or adverse events (including
renal impairment).
Intrathecal/Intraventricular Colistimethate
Sodium
A case series reviewing 24 patients with MDR A. baumannii
CNS infections demonstrated an 83% clinical cure rate with
intrathecal/intraventricular use of colistimethate sodium, with
a 17% mortality rate [47]. Early initiation of treatment
(within 2 days) was associated with survival as compared
with later-onset treatment. Intrathecal/intraventricular colisti-
methate sodium was used as monotherapy in 11 patients,
with high clinical cure rates (91%). Adverse events included
seizures and chemical ventriculitis in four patients. Long-term
survival and neurological outcomes of these patients were
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not described. Several case reports evaluating intrathecal/
intraventricular colistimethate sodium for the treatment of
MDR P. aeruginosa CNS infections have also shown favour-
able results [111–113]. The small number of patients and the
possibility of publication bias should be considered when
interpreting these results.
Polymyxin B Haemoperfusion
Haemoperfusion with polymyxin B bound to polystyrene
ﬁbres, to exploit the endotoxin-binding capacity of polymyx-
ins, is a neglected intervention in the West [114]. This inter-
vention was suggested and is commonly used in Japan in the
treatment of sepsis. A systematic review of the published
evidence included mostly trials conducted in Japan, and
showed a signiﬁcant reduction in all-cause mortality with
polymyxin B haemoperfusion in sepsis (risk ratio 0.50;
95% CI 0.37–0.68) among 354 patients in RCTs [115]. A
more recent multicentre RCT conducted in Italy, including
64 patients with severe sepsis or septic shock undergoing
emergency surgery for intra-abdominal infection, showed a
similar reduction in all-cause mortality (adjusted hazard
ratio 0.36; 95% CI 0.16–0.80) [116]. As expected, haemody-
namic parameters improved. Although the last RCT was
stopped for beneﬁt at the ﬁrst interim analysis, there is
probably a place for further RCTs to establish the safety and
effects of polymyxin B haemoperfusion in severe sepsis with
contemporary critical care.
Implications for Practice and Further
Research
Colistimethate sodium should be given to patients with infec-
tions caused by Gram-negative bacteria susceptible only to
colistin . Colistimethate sodium should not be used to treat
infections caused by bacteria susceptible to b-lactams or qui-
nolones; currently available studies point to a higher mortality
rate with colistimethate sodium, especially among bacterae-
mic patients and with infections caused by carbapenem-resis-
tant K. pneumoniae [80,81,117]. It is impossible to comment
on the choice between colistimethate sodium and aminogly-
cosides when bacteria are susceptible to both. As for colisti-
methate sodium, there is not enough evidence on
aminoglycoside monotherapy in sepsis and bacteraemia
[118,119], and observational studies point at inferiority vs. b-
lactams [120]. Empirical treatment with colistimethate sodium
should be considered for patients at high risk for infection by
carbapenem-resistant bacteria with severe sepsis [121], given
the large beneﬁt of covering empirical antibiotic treatment
[122]. Although colistimethate sodium has been given in com-
bination with b-lactams in most cohorts to date, it is difﬁcult
to recommend combination treatment for bacteria suscepti-
ble only to colistin , owing to concerns about further resis-
tance induction and because in vitro data have not been
translated into clinical beneﬁt to date. Colistimethate sodium
inhalation may be added to systemic antibiotic treatment in
the treatment of VAP, although the clinical beneﬁt of this
intervention is not proven. Given the lack of other treatment
options, intrathecal or intraventricular colistimethate sodium
should be considered for patients with meningitis caused by
carbapenem-resistant Gram-negative bacteria.
In Table 2 we summarize the studies that we believe are
needed to further deﬁne the place of colistimethate sodium
in clinical practice. The urgent need for such trials is empha-
sized by the increased mortality rate with tigecycline, one of
the few other antibiotic options for the treatment of carba-
penem-resistant Enterobacteriaceae, in RCTs [123]. Perhaps
most importantly, methods to prevent the emergence and
spread of MDR Gram-negative bacteria should be devised
and implemented.
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Table S1. Deﬁnitions of renal failure in clinical studies
evaluating colistin.
TABLE 2. Further studies needed to answer unsolved ques-
tions
RCTs assessing intravenous CMS vs. CMS plus carbapenem for the treatment
of strains susceptible only to colistin
RCTs assessing the addition of CMS to empirical therapy regimens in patients at
high risk for MDR Gram-negative infections
RCTs assessing the effectiveness of adjunctive nebulized CMS for the treatment
of nosocomial pneumonia caused by to MDR Gram-negative bacteria
PK studies on CMS and formed colistin and analysis of PK and outcome data
stratiﬁed by severity of illness
Studies assessing risk factors for the development of resistance to colistin,
including dosing and combination treatment
Trials comparing CMS with aminoglycosides, for infections such as those caused
by carbapenem-resistant Klebsiella pneumoniae, which are frequently susceptible
only to colistin and an aminoglycoside
RCTs assessing the effect of polymyxin B haemoperfusion in addition to the
optimal standard of care among critically ill patients with sepsis
CMS, colistimethate sodium; MDR, multidrug-resistant; PK, pharmacokinetic;
RCT, randomized controlled trial.
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